Equities

Medipharm Labs Corp

Medipharm Labs Corp

Actions
  • Price (EUR)0.0446
  • Today's Change0.00 / 0.00%
  • Shares traded21.76k
  • 1 Year change-14.40%
  • Beta--
Data delayed at least 15 minutes, as of Sep 20 2024 20:55 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Balance sheet Back to Overview

In millions of CAD
(except for per share items)
Fiscal data as of Dec 31 2023202320222021
ASSETS
Cash And Short Term Investments182434
Total Receivables, Net5.871317
Total Inventory9.907.7811
Prepaid expenses0.830.691.06
Other current assets, total2.061.732.48
Total current assets374766
Property, plant & equipment, net251826
Goodwill, net------
Intangibles, net1.030.040.04
Long term investments----0
Note receivable - long term--00.12
Other long term assets1.0000.75
Total assets646592
LIABILITIES
Accounts payable2.133.542.99
Accrued expenses4.913.674.15
Notes payable/short-term debt0.330.520
Current portion long-term debt/capital leases1.900.080.11
Other current liabilities, total1.601.651.63
Total current liabilities119.468.88
Total long term debt0.070.030.10
Total debt2.300.630.22
Deferred income tax------
Minority interest------
Other liabilities, total--00.24
Total liabilities119.499.22
SHAREHOLDERS EQUITY
Common stock200191191
Additional paid-in capital------
Retained earnings (accumulated deficit)(147)(135)(107)
Treasury stock - common------
Unrealized gain (loss)------
Other equity, total(0.04)00.03
Total equity535683
Total liabilities & shareholders' equity646592
Total common shares outstanding401282274
Treasury shares - common primary issue000
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.